GIL 2026 | Frost & Sullivan awards Chengdu Shibekang the 2026 Frost & Sullivan Global Cardiovascular, Respiratory and New Drug Development Annual Company Award

Aroop Zutshi, President and Managing Partner of Frost & Sullivan Global and Executive Director of the Global Board of Directors, and Meng Yi, Chair of the Frost & Sullivan Growth Strategy Expert Committee, former General Manager and Vice Chairman of HSBC Global Banking China, presented the award to Chengdu Shibekang Biopharmaceutical Technology Co., Ltd.

Chengdu Shibekang Biopharmaceutical Technology Co., Ltd. was established in 2015 and is headquartered in Chengdu. Adhering to the mission of “giving benefits to all, doubling health protection”, the company upholds the values of “people-oriented, innovation-driven, and innovation supreme”. Oriented by clinical needs, it adheres to the strategic positioning of modified differentiated research and development. Driven by innovation, it focuses on diseases such as cardiovascular and respiratory diseases, aiming to become a world-class leader in differentiated innovation of new drugs, develop better new drugs, benefit all people, and protect human health more effectively.

It is reported that the company has developed the only full life cycle solution for pan-thrombotic diseases in China, coveringlipid plaque formation, platelet activation and aggregation, and coagulation cascade reactions. The indications include stroke, myocardial infarction, acute coronary syndrome, pulmonary embolism, deep vein thrombosis, and peripheral artery occlusion. Simultaneously, it advances its global development strategy, and several core innovative drugs have started the Sino-US dual registration process.SBK002It has received FDA IND approval, and the research results were presented at the 2026 American College of Cardiology (ACC). SBK009 has completed Phase I clinical trials in China and has started FDA IND application. SBK019’s pre-clinical research was selected for the “Breakthrough Basic Research” session at the 2025 American Heart Association (AHA) Scientific Conference. SBK013 will complete Phase I clinical trials in China in September 2026 and submit FDA IND simultaneously. S016’s research results were presented at the 2026 European Society of Cardiology (ESC) conference.

In the respiratory system field, the company focuses on airway mucus regulation mechanisms, targeting diseases such as chronic obstructive pulmonary disease, asthma, allergic rhinitis, and post-infectious cough. Through various dosage forms including injections, oral administration, nebulization, and spraying, it develops differentiated treatment plans. The core pipelineSBK007It has completed Phase II clinical trials in China and will soon start Phase III clinical trials, and has also received FDA IND approval. The research results of SBK007 were presented at the 2026 European Allergy and Asthma Conference (EAACI). SBK001 has passed the initial ethical review by the lead unit and will enter Phase III clinical trials, with research results selected for the 2026 European Respiratory Society (ARS) conference. Shibekang’s independently developed A-MetaForge™ AI metabolic differentiation platform, based on over 100 million experimental verification data, can accurately identify molecular metabolic defects and perform AI generation and repair. It designs superior new molecules from the source, achieving dual-pathway collaboration from “predicting problems” to “solving problems”, providing strong impetus for source-based innovation in drugs.

Shibekang continues to gain widespread recognition from the industry and capital markets due to solid clinical data and differentiated pipeline layout. The company has been recognized as a National High-tech Enterprise and a “Specialized, Sophisticated, Innovative, and High-quality” small and medium-sized enterprise in Sichuan Province. At the pipeline development stage, it has planned clinical strategies in multiple regions including China, the US, and Europe, and conducted research planning around major global regulatory markets. By accumulating international clinical data, it enhances the global applicability of products. Looking to the future, Shibekang takes patients as the core and innovation as the engine. Relying on its full lifecycle management capabilities for chronic diseases and the technical advantages of the AI metabolic platform, it is accelerating its transition from “new in China” to “new globally”, providing more Chinese solutions for patients with cardiovascular, cerebrovascular, and respiratory diseases worldwide.